The Market for Speech and Freedom of Expression. Rethinking Antitrust Responses to Platform Content Control in the Age of AI
Ljubljana Law Review · 19.11.2026 · 86 (1) · 23-52
DOI: 10.51940/2026.1.23-52 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ljubljana Law Review, online erschienen am 19.11.2026. Verfasst von Yibo Li. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This article argues that freedom of expression must be understood as a competition con-cern in digital platform ecosystems and proposes an analytical framework to assess ex-pressive competition. By developing the concept of a “market for speech”, this article introduces a competition law construct capable of capturing non-economic expressive harms to consumer welfare. It then analyses both inter-platform and intra-platform com-petition in markets for speech, explaining why antitrust intervention in platform content control is necessary to preserve meaningful conditions for expression. To illustrate how the proposed framework can be translated into doctrinally grounded examples of harm, it examines two illustrative forms of abusive conduct and shows how established doctrine under Article 102 TFEU can accommodate them when reframed for markets for speech.
Zitieren
APA
Li, Y. (2026). The Market for Speech and Freedom of Expression. Rethinking Antitrust Responses to Platform Content Control in the Age of AI. Ljubljana Law Review, 86(1), 23-52. https://doi.org/10.51940/2026.1.23-52
Vancouver
Li Y. The Market for Speech and Freedom of Expression. Rethinking Antitrust Responses to Platform Content Control in the Age of AI. Ljubljana Law Review. 2026;86(1):23-52. doi:10.51940/2026.1.23-52
BibTeX
@article{Li2026,
author = {Li, Yibo},
title = {The Market for Speech and Freedom of Expression. Rethinking Antitrust Responses to Platform Content Control in the Age of AI},
journal = {Ljubljana Law Review},
year = {2026},
volume = {86},
number = {1},
pages = {23--52},
doi = {10.51940/2026.1.23-52}
}
EUVIMED